What is Inhalation Sciences Sweden AB Days Payable?
Inhalation Sciences Sweden ABXSAT:ISAB +5.69%29 Days Payable is 43.19 as of Mar. 2026, which is 81% below its 10-year median of 229.16. GuruFocus rates XSAT:ISAB with a GF Score™ of 29/100 and a GF Value™ of kr0.39 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 796 Medical Devices & Instruments companies, Inhalation Sciences Sweden AB ranks better than 78.02% on this metric.
The historical rank and industry rank for Inhalation Sciences Sweden AB's Days Payable or its related term are showing as below:
XSAT:ISAB'
s Days Payable Range Over the Past 10 Years
Min: 61.05 Med: 229.16 Max: 761.5
Current: 150.01
During the past 11 years, Inhalation Sciences Sweden AB's highest Days Payable was 761.50. The lowest was 61.05. And the median was 229.16.
XSAT:ISAB's Days Payable is ranked better than 78.02% of 796
companies
in the Medical Devices & Instruments industry
Industry Median: 67.97
vs XSAT:ISAB: 150.01
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSAT:ISAB vs ABT, SYK, MDT: Days Payable Comparison
For the Medical Devices subindustry, Inhalation Sciences Sweden AB's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Inhalation Sciences Sweden AB Days Payable vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Inhalation Sciences Sweden AB's Days Payable distribution charts can be found below:
* The bar in red indicates where Inhalation Sciences Sweden AB's Days Payable falls into.
Inhalation Sciences Sweden AB Days Payable Calculation
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Inhalation Sciences Sweden AB (XSAT:ISAB) has a Days Payable of 43.19 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Inhalation Sciences Sweden AB and its competitors. This is 81% below median its historical median of 229.16. Over the past decade, Inhalation Sciences Sweden AB's Days Payable has ranged from 61.05 to 761.50. According to the industry distribution chart, Inhalation Sciences Sweden AB ranks #175 out of 796 companies in the Medical Devices & Instruments industry, placing it in the top 22%.
Is Inhalation Sciences Sweden AB's Days Payable too high?
Inhalation Sciences Sweden AB's current Days Payable of 43.19 is 81% below median its 10-year median of 229.16. Over the past 10 years, this metric has ranged from a low of 61.05 to a high of 761.50. The Medical Devices & Instruments industry median Days Payable is 67.97. Inhalation Sciences Sweden AB's value of 43.19 is 36.5% below this industry median. Based on the distribution chart, Inhalation Sciences Sweden AB ranks #175 out of 796 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Inhalation Sciences Sweden AB has a GF Score™ of 29/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Inhalation Sciences Sweden AB's Days Payable compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Inhalation Sciences Sweden AB ranks #175 out of 796 companies for Days Payable. This places Inhalation Sciences Sweden AB in the top 22% of its industry — outperforming the majority of peers. The industry median Days Payable is 67.97. Inhalation Sciences Sweden AB's value of 43.19 is 36.5% below this benchmark. Historically, Inhalation Sciences Sweden AB's own Days Payable has ranged from 61.05 to 761.50 over the past decade. While the company's 10-year median is 229.16 vs. the industry median of 67.97, Inhalation Sciences Sweden AB has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Devices & Instruments company?
The median Days Payable among Medical Devices & Instruments companies is 67.97, based on 796 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Inhalation Sciences Sweden AB's current Days Payable of 43.19 is 36.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Inhalation Sciences Sweden AB and its competitors. For the Medical Devices & Instruments industry, the median Days Payable is 67.97 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Inhalation Sciences Sweden AB's current Days Payable is 43.19, which is 81% below median its own 10-year median of 229.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Inhalation Sciences Sweden AB stock overvalued right now?
Based on GuruFocus' analysis, Inhalation Sciences Sweden AB (XSAT:ISAB) is currently considered Possible Value Trap. The stock's GF Value™ is kr0.39, compared to a current price of kr0.22 — trading 42.8% below its estimated fair value. The current Days Payable is 43.19, which is 81% below median its 10-year median of 229.16 and 36.5% below the Medical Devices & Instruments industry median of 67.97. Inhalation Sciences Sweden AB's overall GF Score™ is 29/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Inhalation Sciences Sweden AB (XSAT:ISAB), the current Days Payable is 43.19 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Inhalation Sciences Sweden AB (XSAT:ISAB) Overvalued in 2026?
Based on GuruFocus' analysis, Inhalation Sciences Sweden AB stock appears to be undervalued.
The current stock price of kr0.22 is trading 42.8% below its estimated GF Value™ of kr0.39.
GuruFocus considers Inhalation Sciences Sweden AB to be Possible Value Trap.
Key valuation signals for XSAT:ISAB:
Days Payable: 43.19 (81% below median its 10-year median of 229.16)
GF Value™: kr0.39 vs. price of kr0.22 (42.8% below fair value)
Industry Position: 36.5% below the Medical Devices & Instruments median (#175 of 796)
No single metric tells the full story. See the XSAT:ISAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Inhalation Sciences Sweden AB Business Description
Inhalation Sciences Sweden AB develops and commercializes patented lab instrument for inhalation research. Its products include PreciseInhale an advanced laboratory system used to measure inhaled particles and their effect on lungs, and LaminarPace tool for drying small amounts of the drug substance.
29GF Score
Get the complete analysis for XSAT:ISAB
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSAT:ISAB has been successfully added to your 
